Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cannara BiotechLOVFF -4.73%86 EV-to-EBIT is 10.09 as of Jul. 31, 2026, which is 3% above its 10-year median of 9.80. GuruFocus rates LOVFF with a GF Score™ of 86/100 and a GF Value™ of $1.22 (Fairly Valued). The stock has 5 warning signs investors should review. Among 692 Drug Manufacturers companies, Cannara Biotech ranks better than 68.35% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cannara Biotech's Enterprise Value for the quarter that ended in May. 2026 was $132.77 Mil.
Cannara Biotech's EBIT for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannara Biotech EV-to-EBIT Related Terms
Cannara Biotech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Cannara Biotech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannara Biotech EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cannara Biotech's EV-to-EBIT falls into.
Cannara Biotech's current Enterprise Value is $136.87 Mil.
Cannara Biotech's EBIT for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannara Biotech (LOVFF) has a EV-to-EBIT of 10.09 as of Jul. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cannara Biotech and its competitors. This is near median its historical median of 9.80. According to the industry distribution chart, Cannara Biotech ranks #219 out of 692 companies in the Drug Manufacturers industry, placing it in the top 31.6%.
Is Cannara Biotech's EV-to-EBIT too high?
Cannara Biotech's current EV-to-EBIT of 10.09 is near median its 10-year median of 9.80. The Drug Manufacturers industry median EV-to-EBIT is 15.77. Cannara Biotech's value of 10.09 is 36% below this industry median. Based on the distribution chart, Cannara Biotech ranks #219 out of 692 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cannara Biotech has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cannara Biotech ranks #219 out of 692 companies for EV-to-EBIT. This puts Cannara Biotech in the upper half of its industry. The industry median EV-to-EBIT is 15.77. Cannara Biotech's value of 10.09 is 36% below this benchmark. While the company's 10-year median is 9.80 vs. the industry median of 15.77, Cannara Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.77, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannara Biotech's current EV-to-EBIT of 10.09 is 36% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cannara Biotech and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannara Biotech's current EV-to-EBIT is 10.09, which is near median its own 10-year median of 9.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Fairly Valued. The stock's GF Value™ is $1.22, compared to a current price of $1.31 — trading 7.4% above its estimated fair value. The current EV-to-EBIT is 10.09, which is near median its 10-year median of 9.80 and 36% below the Drug Manufacturers industry median of 15.77. Cannara Biotech's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current EV-to-EBIT is 10.09 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannara Biotech (LOVFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued.
The current stock price of $1.31 is trading 7.4% above its estimated GF Value™ of $1.22.
GuruFocus considers Cannara Biotech to be Fairly Valued.
Key valuation signals for LOVFF:
EV-to-EBIT: 10.09 (near median its 10-year median of 9.80)
GF Value™: $1.22 vs. price of $1.31 (7.4% above fair value)
Industry Position: 36% below the Drug Manufacturers median (#219 of 692)
No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
86GF Score
Get the complete analysis for LOVFF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LOVFF has been successfully added to your 
